MAWAG
CRSP icon

Mid-American Wealth Advisory Group’s CRISPR Therapeutics CRSP Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20
Closed -$973 – 103
2025
Q2 		$973 Buy
+20
New +$774 ﹤0.01% 292

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Mid-American Wealth Advisory Group's CRSP Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 20 shares — an estimated $973 sold.

Mid-American Wealth Advisory Group first reported a position in CRSP in Q2 2025 and held it in 1 quarter. The position peaked at $973 in Q2 2025. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 20 CRISPR Therapeutics shares in Q3 2025, an estimated $973.
  • Mid-American Wealth Advisory Group first reported a position in CRISPR Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's CRISPR Therapeutics position peaked at $973 in Q2 2025.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.